April 13, 2021 -- Repertoire Immune Medicines has completed a round of financing, raising $189 million to further expand its Decode discovery platform, accelerate its clinical and preclinical pipeline, expand its team, and enhance its manufacturing capabilities.
The Decode platform aims at decoding the interactions between T cells and antigens to create new classes of immune medicines for cancer, immune disorders, infectious diseases, and other conditions. The platform allows for in-depth characterization of T cell receptor-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines, according to the company.
The funding will also support the advancement of multiple clinical programs in immuno-oncology using Repertoire's proprietary antigen-primed multiclonal cytokine-enhanced T-cell products in solid tumors. The company's Prime interleukin-15 (IL-15) program in advanced metastatic solid tumors is ongoing, and a data readout is expected later this year.
Meanwhile, the company anticipates initiating a clinical program for its Prime IL-12 program in human papillomavirus (HPV)-16+ solid tumors by mid-year.
The company was founded by Flagship Pioneering and has since raised more than $350 million since its launch in December 2019.
Copyright © 2021 scienceboard.net